Boston Scientific (BSX) Garnering Bullish Views Amid Penumbra Acquisition
The analyst attributed his rating to the company’s strategic acquisition of Penumbra (PEN), which he believes will bolster the business’s durability.
Boston Scientific Corp (BSX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Impax Asset Management Ian Simm | 1,723,927 | $164,376,439 | -1% | 1.03% |
| 2. | Bourgeon Capital John Zaro | 3,693 | $352,128 | +15% | 0.06% |
| 3. | Bayforest Capital Theodoros Tsagaris | 652 | $62,168 | -60% | 0.05% |
| 4. | Sivik Global Healthcare Krishen Sud | 70,000 | $6,675 | 1.94% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $90.29 | 50 | $4,514.60 | 148,168 | 2024-12-03 | Filing | |
| $41.98 | 25,000 | $1,049,450.00 | 25,000 | 2021-11-15 | Filing | |
| $27.50 | 13 | $357.50 | 32,337 | 2017-09-01 | Filing | |
| $27.80 | 30 | $834.00 | 32,324 | 2017-06-16 | Filing | |
| $25.52 | 29 | $740.08 | 32,294 | 2017-04-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $101.55 | 17,313 | $1,758,188.82 | 23,600 | 2025-12-01 | Filing | |
| $98.28 | 12,891 | $1,266,977.75 | 24,134 | 2025-11-06 | Filing | |
| $99.14 | 29,472 | $2,921,895.34 | 178,342 | 2025-11-03 | Filing | |
| $99.76 | 16,928 | $1,688,749.13 | 207,814 | 2025-11-03 | Filing | |
| $100.75 | 3,600 | $362,693.16 | 224,742 | 2025-11-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 139,685,997 | $13,319,059,814 | 0.19% | |
| 2. | 14,872,126 | $1,418,057,213 | 0.23% | |
| 3. | 9,085,528 | $866,305,096 | 0.28% | |
| 4. | 5,468,295 | $521,401,965 | 0.31% | |
| 5. | 5,444,549 | $519,137,739 | 1.11% |
News See All
12 Best Medical Devices Stocks to Invest In According to Hedge Funds
It is challenging to identify segments within the markets that appear to be defensive plays, yet offer innovation potential.
Boston Scientific Corporation (BSX): A Bull Case Theory
We came across a bullish thesis on Boston Scientific Corporation on R. Dennis’s Substack by OppCost.
Oppenheimer Questions Valuation of Boston Scientific’s $14.5 Billion Penumbra Deal
Boston Scientific Corporation (NYSE:BSX) is one of the best mid-cap growth stocks to buy right now.
14 Best Mid-Cap Growth Stocks to Buy Right Now
On January 8, Nancy Prial, Co-CEO & Senior Portfolio Manager at Essex Investment Management, appeared on CNBC and suggested she sees significant upside in 2026 for undiscovered small- and midcap firms...
Boston Scientific (BSX) Expands Urology Portfolio with Valencia Deal, Analysts Emphasize Organic Growth
On January 12, 2026, Boston Scientific Corporation (NYSE:BSX) shared an expansion update, announcing a definitive agreement to acquire Valencia Technologies.
This is Why Wall Street Firms are Bullish on Boston Scientific Corporation (BSX)
Boston Scientific Corporation (NYSE:BSX) is one of the best blue-chip stocks to buy for 2026.
What Are the Best Stocks to Buy Right Now?
As 2026 unfolds, global markets stand at a crossroads.
10 Best Blue Chip Stocks to Buy for 2026
Blue-chip stocks are set to dominate the pace and direction of the US equity market.
A Strong Growth Profile Gives Boston Scientific Corp. (BSX) a Favorable Outlook
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the third quarter of 2025. A copy of the letter can ...
Hedge Fund Resource Center Billionaire Hedge Funds
